RhumbLine Advisers
INMB icon

RhumbLine Advisers’s INmune Bio INMB Stock Holding History

RhumbLine Advisers’s Portfolio INMB Stock Details INMB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		– Sell
-8,741
Closed -$14.2K – 4099
2026
Q2 		$14.2K Sell
8,741
-10,871
-55% -$15K ﹤0.01% 3856
2026
Q1 		$22.2K Sell
19,612
-7,915
-29% -$11.3K ﹤0.01% 3710
2025
Q4 		$42.9K Buy
27,527
+4,878
+22% +$8.7K ﹤0.01% 3659
2025
Q3 		$46.9K Buy
22,649
+313
+1% +$716 ﹤0.01% 3670
2025
Q2 		$51.6K Buy
22,336
+3,183
+17% +$23.4K ﹤0.01% 3665
2025
Q1 		$150K Buy
19,153
+2,409
+14% +$19.1K ﹤0.01% 3250
2024
Q4 		$78.2K Buy
16,744
+2,424
+17% +$12.6K ﹤0.01% 3545
2024
Q3 		$77.2K Buy
14,320
+547
+4% +$3.89K ﹤0.01% 3584
2024
Q2 		$121K Buy
+13,773
New +$136K ﹤0.01% 3457

Other funds holding INMB

Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.76T AUM
Morgan Stanley
Morgan Stanley New York $1.96T AUM 27.49% 1-Year Est. Return
BlackRock
BlackRock New York $6.79T AUM 37.06% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $73.4B AUM 32.8% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return
Jane Street
Jane Street New York $1.19T AUM 51.51% 1-Year Est. Return
Raymond James Financial
Raymond James Financial St Petersburg, Florida $375B AUM 21.05% 1-Year Est. Return
Vanguard Fiduciary Trust
Vanguard Fiduciary Trust Malvern, Pennsylvania $463B AUM
State Street
State Street Boston, Massachusetts $3.44T AUM 36.12% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $765B AUM 28.39% 1-Year Est. Return

RhumbLine Advisers's INMB Position: Q3 2026 in Review

RhumbLine Advisers sold out of INmune Bio (INMB) in Q3 2026, closing a stake of 8,741 shares — an estimated $14.2K sold.

RhumbLine Advisers first reported a position in INMB in Q2 2024 and held it in 9 quarters. The position peaked at $150K in Q1 2025. 46 funds tracked by Wall St. Rank hold INMB as of Q3 2026.

  • RhumbLine Advisers reported no remaining INmune Bio position as of Q3 2026 after selling out during the quarter.
  • RhumbLine Advisers sold 8,741 INmune Bio shares in Q3 2026, an estimated $14.2K.
  • RhumbLine Advisers first reported a position in INmune Bio in Q2 2024 and held it in 9 quarters.
  • RhumbLine Advisers's INmune Bio position peaked at $150K in Q1 2025.
  • 46 funds tracked by Wall St. Rank held INmune Bio as of Q3 2026.

Based on RhumbLine Advisers's 13F filing for Q3 2026, filed 10 Nov 2026.